Abstract
Post-spinal anesthesia hypotension during cesarean delivery poses significant risks to maternal cardiac output and fetal oxygenation. Although phenylephrine (PE) is the standard vasopressor, its use is linked to an increased incidence of maternal bradycardia. In contrast, norepinephrine (NE) offers a more favorable hemodynamic profile and is emerging as a promising alternative. This systematic review and meta-analysis of 18 randomized controlled trials compared NE and PE for the prevention and treatment of post-spinal hypotension in cesarean section parturients. Our findings demonstrate that while NE and PE are equally effective in managing hypotension, NE significantly reduces the incidence of maternal bradycardia (OR = 0.49 [CI: 0.38 to 0.62]) and shows a trend toward fewer adverse maternal events, such as dizziness and reactive hypertension. Additionally, neonatal outcomes indicated a lower birth weight with NE—although still within the normal range—along with tendencies toward lower umbilical arterial lactate levels and improved umbilical vein blood gas pH. These results support NE as a viable alternative to PE, particularly for lowering the incidence of maternal bradycardia, and provide crucial evidence for updating clinical practice guidelines to enhance maternal and neonatal care during cesarean deliveries.
Systematic review registration ID: CRD42024593459 https://www.crd.york.ac.uk/PROSPERO/view/CRD42024593459
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO2/view/CRD42024593459
Funding Statement
This study was funded by DOST-SEI as one of the authors is a scholarship grantee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at PubMed and Scopus
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* These authors share first authorship
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.